arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Aquestive Therapeutics, Inc.

AQST
$3.66 ▼ -0.13 (-3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
40 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Aquestive Therapeutics, Inc. shows mixed fundamentals. However, watch Operating Margin (%) and Profit Margin (%) which show concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $459.5M
Dividend Yield —
Revenue Growth -41.0% ↘
Op. Margin -191.5% ↘
ROIC 91.4% ↘
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.78
info Valuation on last close. End-of-day price, Nov 5, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.56M
↓ -41.0% —
Net Income Profit after all expenses
$-8.06M
↑ +64.9% —
Operating Margin Operating profit as % of sales
-191.5%
↓ -221.8% 1th
FCF / Share Free cash flow per share
$-0.06
↑ +21.3% —
Long-Term Debt Long-term obligations
$55.00M
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↑
100
Financial Health →
64
Cash Quality ↑
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 40 quarters